TKMR Key Stats
|Revenue (Quarterly YoY Growth)||-4.78%|
|EPS Diluted (TTM)||1.541|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||27.07M|
|Gross Profit Margin (Quarterly)||-85.85%|
|Profit Margin (Quarterly)||-199.3%|
|Dividend Yield (TTM)||0.00%|
|Payout Ratio (TTM) Pro||Go Pro|
- Tekmira Pharmaceuticals Enters Oversold Territory (TKMR) The Street Dec 11
- TKMR: Tekmira Exited 3Q13 With Very Strong Balance Sheet Nov 14
- Tekmira Provides Corporate Update and Announces Third Quarter 2013 Results noodls Nov 13
- Tekmira Announces New Preclinical Data from Anti-Viral Programs noodls Nov 12
- Tekmira's Partner Initiates Phase III Trial With LNP-Enabled Patisiran (ALN-TTR02) noodls Nov 11
- Tekmira Conference Call and Webcast Advisory: Corporate Update and Third Quarter Financial Results noodls Nov 7
- Tekmira Announces Closing of Underwriters' Full Over-Allotment Option noodls Nov 1
- Tekmira Pharma (TKMR) Prices 3.75M Offering at $8/Share Street Insider Oct 17
- Tekmira Pharmaceuticals Corp (TKMR) halted with news pending Street Insider Oct 17
- Tekmira Pharma (TKMR) Announces Stock Offering Street Insider Oct 16
TKMR Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Tekmira Pharmaceuticals is up 44.69% over the last year vs S&P 500 Total Return up 28.99%, Spectrum Pharmaceuticals down 15.48%, and Alnylam Pharmaceuticals up 217.6%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for TKMR
Pro Strategies Featuring TKMR
Did Tekmira Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Tekmira Pharmaceuticals Corporation develops ribonucleic acid interference therapeutic product candidates as well as provides its lipid nanoparticle delivery technology to pharmaceutical partners in the Canada.